Bulk Inquiry
BAY 1895344
Axon 2918
CAS:
1876467-74-1
- Optical Purity: Optically pure
- Soluble in 0.1N HCl(aq) and DMSO
- MF: C20H21N7O
- MW: 375.43
Description
BAY 1895344 is a potent, highly selective and orally available ATR inhibitor (IC50 value of 7 nM), which potently inhibits proliferation of a broad spectrum of human tumor cell lines (median IC50 value of 78 nM). BAY 1895344 exhibits strong in vivo anti-tumor efficacy in monotherapy in a variety of xenograft models of different indications that are characterized by DDR deficiencies, inducing stable disease in ovarian and colorectal cancer or even complete tumor remission in mantle cell lymphoma models.
More Information
| Parent CAS No. | 1876467-74-1 |
|---|---|
| Chemical Name | (R)-3-Methyl-4-(4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-2-yl)morpholine |
| SMILES | C1(N2CCOC[C@H]2C)=NC2C(C3=CC=NN3)=NC=CC=2C(C2N(C)N=CC=2)=C1 |&1:6,r| |
| MFCD | N.A. |
| InChi | InChI=1S/C20H21N7O/c1-13-12-28-10-9-27(13)18-11-15(17-5-8-23-26(17)2)14-3-6-21-20(19(14)24-18)16-4-7-22-25-16/h3-8,11,13H,9-10,12H2,1-2H3,(H,22,25)/t13-/m1/s1 |
| InChiKey | YBXRSCXGRPSTMW-CYBMUJFWSA-N |
| CID | 118869362 |
| Short Description | ATR inhibitor |
References
- AM Wengner et al. Abstract 836: ATR inhibitor BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride in preclinical tumor models. Proceedings: AACR Annual Meeting 2017; April 1-5, 2017.
- UT Luecking et al. Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models. Proceedings: AACR Annual Meeting 2017; April 1-5, 2017.
Other Categories
Get a Quote for
Loading...
Are you sure you would like to remove this item from the shopping cart?
This item is a part of the approved quote. Removing it will remove all quote items from the cart.